DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice

被引：0

作者：

Matsumoto, G ^{[1
]}

Rahman, MA ^{[1
]}

Muta, M ^{[1
]}

Nakamura, T ^{[1
]}

Bando, H ^{[1
]}

Saji, S ^{[1
]}

Tsuruta, K ^{[1
]}

Okamoto, A ^{[1
]}

Toi, M ^{[1
]}

机构：

[1] Tokyo Metropolitan Komagome Hosp, Dept Surg, Bunkyo Ku, Tokyo 1138677, Japan

来源：

ONCOLOGY REPORTS | 2004年 / 12卷 / 02期

关键词：

cyclooxygenase-2; DFU; breast cancer;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cyclooxygenase-2 (COX-2) inhibitors are regarded as potentially important in strategies for cancer treatment. However, the precise mechanisms of these anti-inflammatory drugs as anti-cancer therapy are still unknown. In this study, we examined the effect of DFU both in vitro on MCF-7 cell growth, as well as in vivo on tumor growth produced by MCF-7 cell injection in mice. DFU has growth inhibitory effects on tumor growth in mice compared to the control group. We examined the tumor tissues for apoptosis and angiogenesis by immunostaining. Apoptosis was detected only in the treatment group. DFU treatment also resulted in the inhibition of angiogenesis, as well as decreased COX-2 expression. Results of this study suggest that inhibitory effects of DFU might be COX-2 dependent.

引用

页码：281 / 285

页数：5

共 50 条

[31] Characterization of etoricoxib, a novel, selective COX-2 inhibitor
Dallob, A
Hawkey, CJ
Greenberg, H
Wight, N
De Schepper, P
Waldman, S
Wong, P
DeTora, L
Gertz, B
Agrawal, N
Wagner, J
Gottesdiener, K
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06): : 573 - 585
[32] Polymorphs and hydrates of Etoricoxib, a selective COX-2 inhibitor
Grobelny, Pawel
Mukherjee, Arijit
Desiraju, Gautam R.
CRYSTENGCOMM, 2012, 14 (18): : 5785 - 5794
[33] COX-2 selective inhibitor inhibits osteoclast differentiation
Ryu, Kakei
Amano, Hitoshi
Iwai, Shinichi
Emori, Haruka
Yamada, Shoji
Oguchi, Katsuji
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 171P - 171P
[34] MCF-7 breast cancer cell line grown in agarose culture for study of COX-2 inhibitors in three-dimensional growth system
Kinder, DH
Aulthouse, AL
CANCER LETTERS, 2004, 205 (01) : 49 - 53
[35] A novel genetic model of selective COX-2 inhibition: Comparison with COX-2 null mice
Yu, Ying
Funk, Colin D.
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2007, 82 (1-4) : 77 - 84
[36] Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice
Zhang, JY
Yuan, JJ
Wang, YF
Bible, RH
Breau, AP
DRUG METABOLISM AND DISPOSITION, 2003, 31 (04) : 491 - 501
[37] Colon cancer cell growth inhibition by treatment with a selective COX-2 inhibitor.
Goldman, AP
Williams, CS
Williams, VP
DuBois, RN
GASTROENTEROLOGY, 1998, 114 (04) : A601 - A601
[38] miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1
Zhao, Yiling
Yang, Fenghua
Li, Wenyuan
Xu, Chunyan
Li, Li
Chen, Lifei
Liu, Yancui
Sun, Ping
TUMOR BIOLOGY, 2017, 39 (02)
[39] Role Of Membrane Cholesterol Content In The Activity Of Cyclooxygenase-2 (COX-2) In MCF-7 Human Breast Cancer Cells
Zhu, Weiwei
Olsher, Michelle
Venegas, Berenice
Tran, Samantha
Chong, Parkson L-G
BIOPHYSICAL JOURNAL, 2009, 96 (03) : 605A - 605A
[40] The effect of cyclooxygenase-2 (COX-2) inhibitor, Celecoxib, on xenograft of hepatocellular carcinoma (HCC) in nude mice.
Tang, TC
Poon, RT
Guan, XY
Fan, ST
CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6149S - 6149S

← 1 2 3 4 5 →